CTLA-4 +49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis

Respiration

Volumn 82, Issue 5, 2011, Pages 439-444

  Song, Bao ^a   Liu, Yanbing ^b   Liu, Jie ^b   Song, Xianrang ^a   Wang, Zhehai ^b   Wang, Mingyu ^b   Zhu, Yufang ^b   Han, Jinxiang ^c  

^a Shandong Provincial Key Laboratory of Radiation Oncology   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocyte antigen 4; Immune response; Non small cell lung cancer; Polymorphism; Prognosis; Survival

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 49A; LYMPHOCYTE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ADVANCED LUNG NON SMALL CELL CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHINESE; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CTLA-4 ANTIGEN; DOWN-REGULATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 81155160898     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000329345     Document Type: Article

References (34)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: American Cancer Society: Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Dillman RO, Herndon J, Seagren SL Eaton WL Jr, Green MR: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J Natl Cancer Inst 1996; 88: 1210-1215. (Pubitemid 26302034)
3. Li CT, Marek M, Guclu SZ, Kim Y, Meshref M, Qin S, Kadziola Z, Krejcy K, Altug S: Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. J Cancer 2011; 2: 52-61.
4. Wauters I, Stroobants S, De Leyn P, D'Hoore I, Nackaerts K, Dooms C, Vansteenkiste J: Impact of FDG-PET-induced treatment choices on long-term outcome in non-small cell lung cancer. Respiration 2010; 79: 97-104.
5. Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183. (Pubitemid 46718402)
6. Wolchok JD, Saenger Y: The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008; 13: 2-9.
7. Thompson CB, Allison JP: The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445-450. (Pubitemid 27508696)
8. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547.
9. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736. (Pubitemid 26102823)
10. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60: 2444-2448. (Pubitemid 30262435)
11. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-Associated antigen 4 (CTLA-4) and granulocyte/ macrophage colony-stimulating factor (GMCSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. Exp Med 1999; 2: 190: 355-366. (Pubitemid 29374833)
12. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-Associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377. (Pubitemid 36842552)
13. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G: Biologic activity of cytotoxic T lymphocyte-Associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712-4717. (Pubitemid 36457795)
14. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Rønningen KS, Guja C, Ionescu-Tîrgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511. (Pubitemid 36648570)
15. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J: CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001; 2: 145-152. (Pubitemid 33674879)
16. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ: MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-smallcell lung cancer. Respiration 2009; 78: 49-55.
17. Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A: CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 2007; 22: 2283-2287. (Pubitemid 350145629)
18. Solerio E, Tappero G, Iannace L, Matullo G, Ayoubi M, Parziale A, Cicilano M, Sansoè G, Framarin L, Vineis P, Rosina F: CTLA4 gene polymorphism in Italian patients with colorectal adenoma and cancer. Dig Liver Dis 2005; 37: 170-175. (Pubitemid 41070535)
19. Dilmec F, Ozgonul A, Uzunkoy A, Akkafa F: Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet 2008; 35: 317-321.
20. Qi P, Ruan CP, Wang H, Zhou FG, Xu XY, Gu X, Zhao YP, Dou TH, Gao CF. CTLA-4 +49A 1 G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese. Int J Colorectal Dis 2010; 25: 39-45.
21. Sun T, Zhou Y, Yang M, Hu Z, Tan W, Han X, Shi Y, Yao J, Guo Y, Yu D, Tian T, Zhou X, Shen H, Lin D: Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008; 68: 7025-7034.
22. Wang L, Li D, Fu Z, Li H, Jiang W, Li D: Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer 2007; 7: 173.
23. Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, Dehaghani AS: Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 2004; 86: 1-7. (Pubitemid 38918893)
24. Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, Wang TE, Cheng AL, Wu MS: Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-Associated lymphoid tissue lymphoma. J Clin Oncol 2006; 24: 3483-3489.
25. Monne M, Piras G, Palmas A, Arru L, Murineddu M, Latte G, Noli A, Gabbas A: Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am J Hematol 2004; 76: 14-18. (Pubitemid 38579532)
26. Hou R, Cao B, Chen Z, Li Y, Ning T, Li C, Xu C, Chen Z: Association of cytotoxic T lymphocyte-Associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep 2010; 37: 515-520.
27. Xiao M, Qi F, Chen X, Luo Z, Zhang L, Zheng C, Hu S, Jiang X, Zhou M, Tang J: Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population.Int J Immunogenet 2010; 37: 27-32.
28. Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, Zhao Y, Gao C: +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010; 71: 83-87.
29. Zheng J, Yu X, Jiang L, Xiao M, Bai B, Lu J, Zhou Y: Association between the Cytotoxic T-lymphocyte antigen 4± 8 49G > A polymorphism and cancer risk: A meta-Analysis. BMC Cancer 2010; 10: 522.
30. Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagita H, Gejyo F, Okumura K, Smyth MJ: Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 2010; 184: 5493-5501.
31. Hurwitz AA, Yu TF, Leach DR, Allison JP: CTLA-4 blockade synergizes with tumorderived granulocyte-macrophage colonystimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998; 95: 10067-10071. (Pubitemid 28415295)
32. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N, Rieckmann P: A polymorphism in the human cytotoxic Tlymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002; 54: 1-8. (Pubitemid 34492947)
33. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-Associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688. (Pubitemid 350206804)
34. Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ: Influence of cytotoxic T lymphocyte-Associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 2008; 31: 586-590.